NNara Capital
Nara Capital is a Barcelona-based multi-strategy private capital firm, founded in 2022 and regulated by the CNMV. It invests through three strategies. NARA Ventures is a €100M venture capital fund of funds, launched in 2024 with Plug and Play. It backs top-quartile VC funds and emerging managers worldwide and can co-invest directly in start-ups. NARA Health invests in early-stage biotech and healthtech start-ups through Nara Health Capital I, FCR, with a portfolio that includes Gyala Therapeutics, Biointaxis and Affirma Biotech. NARA Sustainability develops solar, wind, biogas and storage projects for the energy transition.
SectorsBiotech, Healthtech, Venture capital funds, Energy transition
VC MapSeed
portfolio by sector8
Healthtech & Bio8
Team
Josep Magdalena
Partner & CEO
Pepe Quintero
Partner
Miguel Eguizábal
Partner
J
Joan Mercadal
Health Partner
Portfolio companies 8
Open 8 as list → On map →
GGyala Therapeutics
entered at Series A, 2024
AAortyx
entered at Series A, 2025
BBiointaxis
led Seed (estimated), 2021
TTesai Care
entered at Seed (estimated), 2024
AAffirma Biotech
led Seed (estimated), 2024
OOneChain Immunotherapeutics
entered at Pre-Series A, 2023
MMiMARK Diagnostics
entered at Seed, 2023
IInnitius
led Series A (estimated), 2023
Funding rounds 10
Open as list →| Date | Company | Round | Amount | Lead |
|---|---|---|---|---|
| 2025-09-15 | Gyala Therapeutics | Series A (estimated) | €3M |
Lead not disclosed
+3 more
|
| 2025-06-12 | Aortyx | Series A | €13.8M |
Ship2B Ventures, Clave Capital
+3 more
|
| 2024-12-20 | Biointaxis | Seed | €1.05M |
Lead not disclosed
+3 more
|
| 2024-12-09 | Tesai Care | Seed (estimated) | €2.77M incl. debt: equity and debt, the split was not disclosed |
Lead not disclosed
+3 more
|
| 2024-10-14 | Gyala Therapeutics | Series A | €540K partial: only one investor's ticket was disclosed |
Lead not disclosed
+3 more
|
| 2024-02-02 | Affirma Biotech | Seed (estimated) | €1.75M |
Nara Capital
+6 more
|
| 2023-06-22 | OneChain Immunotherapeutics | Pre-Series A | €6.7M |
Invivo Capital
+5 more
|
| 2023-06-07 | MiMARK Diagnostics | Seed | approximately €1.72M |
Lead not disclosed
+7 more
|
| 2023-02-15 | Innitius | Series A (estimated) | €1.8M |
Clave Capital, Nara Capital
+5 more
|
| 2021-11-03 | Biointaxis | Seed (estimated) | €880K |
Nara Capital
+3 more
|